This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bionomics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Bionomics's earnings have been declining at an average annual rate of -3.4%, while the Biotechs industry saw earnings growing at 16% annually. Revenues have been declining at an average rate of 42.6% per year.

Wichtige Informationen

-3.4%

Wachstumsrate der Gewinne

27.8%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	9.6%
Wachstumsrate der Einnahmen	-42.6%
Eigenkapitalrendite	-52.2%
Netto-Marge	-413.9%
Letzte Ertragsaktualisierung	31 Dec 2022

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Aufschlüsselung der Einnahmen und Ausgaben

Wie Bionomics Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

ASX:BNO Einnahmen, Ausgaben und Erträge (AUD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten
31 Dec 22	6	-25	7
30 Sep 22	6	-23	7
30 Jun 22	6	-22	8
31 Mar 22	3	-22	8
31 Dec 21	0	-22	8
30 Sep 21	1	-15	7
30 Jun 21	1	-9	6
31 Mar 21	1	-4	5
31 Dec 20	2	1	5
30 Sep 20	2	-3	5
30 Jun 20	3	-6	5
31 Dec 19	6	-5	5
30 Sep 19	7	-8	6
30 Jun 19	7	-10	8
31 Mar 19	8	-20	11
31 Dec 18	8	-28	11
30 Sep 18	10	-27	11
30 Jun 18	12	-25	11
31 Mar 18	19	-15	9
31 Dec 17	27	-6	8
30 Sep 17	27	-6	8
30 Jun 17	27	-7	8
31 Mar 17	22	-12	10
31 Dec 16	16	-17	12
30 Sep 16	18	-17	11
30 Jun 16	19	-17	11
31 Mar 16	19	-19	10
31 Dec 15	18	-21	9
30 Sep 15	17	-19	9
30 Jun 15	15	-17	9
31 Mar 15	22	-6	7
31 Dec 14	29	4	5
30 Sep 14	28	4	5
30 Jun 14	27	3	5
31 Mar 14	19	-5	5
31 Dec 13	12	-13	5
30 Sep 13	12	-11	5
30 Jun 13	12	-10	5
31 Mar 13	13	-7	5
31 Dec 12	13	-4	4
30 Sep 12	12	-3	4

Qualität der Erträge: BNO is currently unprofitable.

Wachsende Gewinnspanne: BNO is currently unprofitable.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: BNO is unprofitable, and losses have increased over the past 5 years at a rate of 3.4% per year.

Beschleunigtes Wachstum: Unable to compare BNO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Erträge im Vergleich zur Industrie: BNO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).

Eigenkapitalrendite

Hohe Eigenkapitalrendite: BNO has a negative Return on Equity (-52.21%), as it is currently unprofitable.

This company listing is no longer active

Bionomics Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings released: AU$0.01 loss per share (vs AU$0.011 loss in FY 2020)

Full year earnings released - AU$0.0082 loss per share

Recent updates

New minor risk - Financial data availability

Bionomics Completes Last Patient Last Visit in the Phase 2B Attune Study for Post-Traumatic Stress Disorder

New major risk - Market cap size

Bionomics Limited Appoints Tim Cunningham as Chief Financial Officer

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)

Is Bionomics (ASX:BNO) In A Good Position To Invest In Growth?

High number of new directors

Bionomics Limited Reports Results in PREVAIL Phase2 Study BNC210

High number of new and inexperienced directors

Bionomics Limited, Annual General Meeting, Nov 16, 2022

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Full year 2022 earnings: EPS and revenues exceed analyst expectations

High number of new and inexperienced directors

High number of new and inexperienced directors

Bionomics Limited announced that it has received $2.794495 million in funding

Bionomics Initiates Phase 2 Prevail Study of Bnc210 for the Acute Treatment of Social Anxiety Disorder

High number of new directors

U.S. Food and Drug Administration Grants Bionomics Fast Track Designation to Bnc210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders

Companies Like Bionomics (ASX:BNO) Are In A Position To Invest In Growth

Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial

Full year 2021 earnings released: AU$0.01 loss per share (vs AU$0.011 loss in FY 2020)

Bionomics Initiates Phase 2B ATTUNE Study of BNC210 in PTSD

Bionomics BNC210 Expansion into Social Anxiety Disorder

Legal Counsel & Company Secretary has left the company

Bionomics Limited has completed a Follow-on Equity Offering in the amount of AUD 15.991634 million.

New 90-day high: AU$0.39

Bionomics Limited Announces Positive BNC210 PK Results for Solid Dose Formulation

Bionomics Limited and EmpathBio Inc Joint Feasibility Assessment

Bionomics Limited announced that it expects to receive AUD 15.991634 million in funding

New 90-day high: AU$0.22

Bionomics Limited Completes Treatment Phase in the MODULATE Clinical Trial

Bionomics Limited Announces Publication of Positive BNC210 Phase 2a Data in Gad Patients

Bionomics Limited Initiates 7-Day Dosing Pharmacokinetic Study of BNC210

Did You Miss Bionomics' (ASX:BNO) 86% Share Price Gain?

Bionomics Limited Licenses Drug Candidate BNC101 to Carina Biotech

Bionomics Limited Announces Director Changes

Bionomics Limited announced that it has received AUD 5.43332 million in funding from Apeiron Investment Group Ltd. and other investors

Full year earnings released - AU$0.0082 loss per share

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Eigenkapitalrendite

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren